NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML

• AMG 176

• NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia

Sponsor

Amgen

---

ClinicalTrials.gov Identifier: NCT02675452

Official Title: A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

First Posted : February 5, 2016

Click here for details on ClinicalTrials.gov

---

MCL-1 Inhibitor AMG 176

MCL-1 Inhibitor AMG 176: National Cancer Institute

View this agent in the NCI Thesaurus

---

Drug: AMG 176

Drug: Azacitidine

Drug: Itraconazole

---

Locations

United States, California

United States, Colorado

United States, Georgia

United States, Illinois

United States, Louisiana

United States, Massachusetts

United States, New Jersey

United States, Texas

United States, Utah

Australia, New South Wales

Australia, Victoria

Canada, Alberta

Canada, Ontario

Europe

Germany

Asia

Japan